EUVIMEDEUVIMED entdecken
Leserbrief

Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”

Rachel E Aubrey iD, Hagit Peretz Soroka, Abha A Gupta, David B Shultz

Cancer · 15.04.2026 · 132 (8)

DOI: 10.1002/cncr.70397 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Cancer, online erschienen am 09.04.2026. Verfasst von Rachel E Aubrey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • University of Toronto, Toronto, Ontario, Canada.
  • Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

ORCID-Profile: Rachel E Aubrey

Zitieren

APA

Aubrey, R. E., Soroka, H. P., Gupta, A. A., & Shultz, D. B. (2026). Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”. Cancer, 132(8). https://doi.org/10.1002/cncr.70397

Vancouver

Aubrey RE, Soroka HP, Gupta AA, Shultz DB. Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”. Cancer. 2026;132(8). doi:10.1002/cncr.70397

BibTeX
@article{Aubrey2026,
  author = {Aubrey, Rachel E and Soroka, Hagit Peretz and Gupta, Abha A and Shultz, David B},
  title = {Reply to “Prognostic factors in neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status”},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {8},
  doi = {10.1002/cncr.70397}
}
Kostenlos starten →